Structure Search


    Online Support

  •  Customer service

    Location: Industrial Info

DAWN trial, extended therapeutic window of stroke to 24 hours!

2017-11-24 来源:转载自第三方
24 November 2017
  Recently, the journal "New England Journal of Medicine" published the results of the DAWN trial, the trial found that thrombectomy can bring better treatment to stroke patients for more than 6 hours. The trial was funded by Stryker Neurovascular, a medical technology company whose purpose was to determine if clinical symptoms and infarct size "mismatch" could be achieved within a longer time window.
  Stroke, a disease that occurs when blood vessels in the brain are blocked by blood clots, has attracted the attention of the general public and the medical community as the number of stroke patients among young adults increases. According to statistics, there are up to 1.7 million deaths each year in China due to stroke, ranking first among the top 10 deaths in China. After stroke, the brain cells die at a rate of 1.9 million per minute. Therefore, doctors need to race against time to get the patient back from their death.
  In general, patients within 3~6 hours after the stroke is the prime time for treatment. Internationally used method is to use drugs to dissolve the clogged blood vessels emboli in order to clear the blood vessels and restore the brain blood supply. Or by surgical means, the stent is sent into the blood vessels to reach the site of disease, remove the clot and restore vascular patency. This treatment can be extended the treatment time to 6~8 hours. While DAWN trial can extend the treatment time to 24 hours.
  In the DAWN experiment, the researchers chose patients who have a stroke within 6 to 24 hours and with cerebral vascular occlusion to implement "thrombectomy". after 90 days of treatment, 49% of 107 patients received treatment were able to do their daily routine independently; in contrast, only 13% of the 99 patients who received standard medical treatment recovered to a similar level. Only 14% of patients who received thrombectomy had neurological decline, compared with 26% of those who received standard therapy.
  The DAWN trial brings good treatment to patients who have had a stroke for more than 6 hours, but it does not mean that we could relax for gold treatment of 6 hours. It is still necessary to shorten the time from the onset of stroke to treatment to obtain the best treatment outcome. Moreover, whether this treatment method is suitable for all stroke patients still needs further tests. Finally, stroke-prone patients require antiplatelet agents such as aspirin (acetylsalicylic acid) and clopidogrel (intermediate 2-thienylethylamine) to prevent the recurrence of stroke.
Related links: Acetylsalicylic acid
Edited by Suzhou Yacoo Science Co., Ltd.


Copyright © 2010 SuZhou Yacoo Science Co., Ltd All Rights Reserved Powered by: Founder International
Yacoo Information Management Platform   用户登录   站内地图